Research Papers:
Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2679 views | HTML 3533 views | ?
Abstract
Ziliang Wang1,3,*, Yang Liu2,3,*, Lili Lu4, Lina Yang1,3, Sheng Yin2,3, Yan Wang1,3, Zihao Qi1,3, Jiao Meng1,3, Rongyu Zang2,3, Gong Yang1,3,5
1Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai 200032, China
2Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
4Department of Biology, Life and Environment Science College, Shanghai Normal University, Shanghai 200023, China
5Central Laboratory, the Fifth People's Hospital of Shanghai Fudan University, Shanghai 200240, China
*These authors have contributed equally to this work
Correspondence to:
Rongyu Zang, e-mail: [email protected]
Gong Yang, e-mail: [email protected]
Keywords: Aurora-A, BRCA2, FBN1, SLUG, Metastasis
Received: September 11, 2014 Accepted: January 08, 2015 Published: February 13, 2015
ABSTRACT
While Aurora-A (Aur A) provokes, BRCA2 restrains primary tumorigenesis, the roles of Aur A and BRCA2 in cancer metastasis remains unclear. Here, we show that the metastatic promoting markers SLUG, FBN1, and MMP2, 9, 13 are either stimulated or suppressed by Aur A or BRCA2, but the metastatic suppressors E-cadherin, β-catenin, and p53 are either inhibited or promoted by Aur A or BRCA2, leading to enhanced or reduced cell migration and invasion. Further study suggests that FBN1 inhibits E-cadherin and β-catenin, but stimulates MMP2, 9, 13. Depletion of SLUG abrogates FBN1 and MMP9, but increases E-cadherin, while p53 decreases both SLUG and FBN1. Animal assays demonstrate that FBN1 promotes both ovarian tumorigenesis and metastasis. Clinically, overexpression of BRCA2 or Aur A in ovarian cancer tissues predicts good or poor overall and disease free survivals. High expression of SLUG or FBN1 indicates poor overall survivals, whereas high expression of FBN1 but not of SLUG predicts poor disease free survival. No significant associations between p53 expression and patient survivals were found. Overall, FBN1, acts at the downstream of Aur A and BRCA2, promotes ovarian cancer metastasis through the p53 and SLUG-associated signaling, which may be useful for ovarian cancer diagnosis and treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3118